Daewoong Acquires Pet Drug and Telemedicine Service Company 'Daewoong Pet'
[Asia Economy Reporter Gong Byung-sun] Daewoong announced on the 19th that it will acquire Daewoong Pet, a company developing new drugs for companion animals, non-face-to-face medical services, and clinical trial support platforms.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Daewoong stated that it acquired the company to enter the companion animal pharmaceuticals and medical services sectors. Daewoong Pet's capital is 528 million KRW, with total assets and total liabilities of 523 million KRW and 56 million KRW, respectively.
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
